在患有脊椎关节炎和相关心脏代谢风险概况的患者中,治疗interleukin-17的向治疗
Rubén Queiro1,2, Elena Aurrecoechea3,4, Sara Alonso Castro5
1Rheumatology and Health Research Institute of the Principality of Asturias (ISPA) Translational Immunology Division, Hospital Universitario Central de Asturias, Oviedo, Spain.
Frontiers in immunology
|August 3, 2023
概括
脊椎关节炎患者通常有心脏代谢障碍. 干白素-17 (IL-17) 阻断,特别是secukinumab,在治疗这些疾病方面表现有前途,并可能降低心血管事件风险.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
背景情况:
- 脊椎关节炎 (SpA) 与心脏代谢疾病 (肥胖,高血压,血脂不良,糖尿病) 的更高率有关.
- 这些并发症可以加剧SPA疾病的活性,增加心血管事件的风险.
- 共享的炎症通路,特别是IL-23/IL-17轴,可能会将SPA和心脏代谢条件联系起来.
研究的目的:
- 审查SPA中炎症和心脏代谢并发症之间的生理联系.
- 评估IL-17阻断与其他治疗对SPA患者心脏代谢参数的影响.
- 在SPA中探索生物疗法和心脏代谢健康之间的双向关系.
主要方法:
- 现有科学文献的叙述性审查.
- 在SPA和心脏代谢疾病中对IL-23/IL-17轴的证据分析.
- 对IL-17阻断 (secukinumab) 和心脏代谢结果的研究进行了审查.
主要成果:
- 用secukinumab阻断IL-17似乎对心脏代谢参数安全,并可能降低心血管事件风险.
- 肥胖不会对secukinumab的疗效和保留产生负面影响;一些研究表明有好处.
- 存在双向关系:生物药物可以改变心脏代谢状态,并影响治疗反应的并发症.
结论:
- 针对IL-17的向疗法,特别是sequinumab,对于患有心脏代谢并发症的SpA患者是有效的.
- 塞库金纽马布可能会提供额外的心脏代谢益处,与其他一些治疗方法 (如TNF阻断) 不同.
- 对于SPA的治疗决定,必须考虑生物疗法与患者心脏代谢特征之间的相互作用.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Rheumatic Heart Disease III: Medical Management
20
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
20
Myocarditis III: Medical Management
9
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
9
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173


